Xenetic Biosciences, Inc. (NASDAQ:XBIO) | WebDisclosure

Basculer en Français

8643	Companies
145615	Keywords
81371	Articles
77973	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

PRESS RELEASE

published on 12/16/2024 at 15:00, 4 months 20 days ago

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Xenetic Biosciences extends Research Funding Agreement with UVA to develop systemic DNase program targeting NETs to improve cancer therapy outcomes

Xenetic Biosciences DNase Program Cancer Therapy Immunotherapy NETs
BRIEF

published on 12/05/2024 at 14:50, 5 months ago

Xenetic Biosciences s'associe à PeriNess pour les services d'essais cliniques

Essais Cliniques Oncologie Biosciences Xénétiques ADNase I PeriNess Ltée.
BRIEF

published on 12/05/2024 at 14:50, 5 months ago

Xenetic Biosciences Partners with PeriNess for Clinical Trial Services

Xenetic Biosciences Clinical Trials Oncology DNase I PeriNess Ltd.
PRESS RELEASE

published on 12/05/2024 at 14:45, 5 months ago

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
Xenetic Biosciences partners with PeriNess to advance clinical proof-of-concept studies for systemic DNase I treatment in pancreatic and colorectal cancers. Collaboration aims to leverage expertize and improve therapeutic responses

Xenetic Biosciences Clinical Development Pancreatic Cancer PeriNess Systemic DNase I
BRIEF

published on 11/22/2024 at 15:20, 5 months 13 days ago

Xenetic Biosciences partage ses connaissances sur l'efficacité de la DNase I dans le traitement du cancer

Traitement Du Cancer Biosciences Xénétiques Données Précliniques ADNase I Blocage Du Point De Contrôle Immunitaire
BRIEF

published on 11/22/2024 at 15:20, 5 months 13 days ago

Xenetic Biosciences Shares Insights on DNase I Efficacy in Cancer Treatment

Xenetic Biosciences Cancer Treatment Preclinical Data DNase I Immune Checkpoint Blockade
PRESS RELEASE

published on 11/22/2024 at 15:15, 5 months 13 days ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, presents positive preclinical data at SITC 39th Annual Meeting. Focus on advancing immune-oncology technologies to treat hard cancers

Cancer Treatment Preclinical Data Immunotherapy SITC 39th Annual Meeting Dr. Reid Bissonnette
BRIEF

published on 11/21/2024 at 14:35, 5 months 14 days ago

Xenetic Biosciences Reports Promising Preclinical Results for DNase I and CAR T Cell Therapy in Melanoma

Preclinical Study Melanoma DNase I CAR T Cells Oncology Therapy
BRIEF

published on 11/21/2024 at 14:35, 5 months 14 days ago

Xenetic Biosciences annonce des résultats précliniques prometteurs pour la thérapie par ADNase I et cellules CAR T dans le mélanome

Étude Préclinique Mélanome ADNase I Cellules CAR-T Thérapie Oncologique
PRESS RELEASE

published on 11/21/2024 at 14:30, 5 months 14 days ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Xenetic presents preclinical data on DNase I and CAR T cells' synergistic effects in treating solid tumors. Results show promise in modulating tumor microenvironment and enhancing therapeutic responses

Preclinical Data Solid Tumors Xenetic DNase I CAR T Cells

Accesswire

Published on 05/05/2025 at 15:10, 4 hours 50 minutes ago

Star Gold Corp. Refocuses Strategy on Longstreet Project
Published on 05/05/2025 at 14:30, 5 hours 30 minutes ago

Gladstone Capital Corporation Earnings Call and Webcast Information
Published on 05/05/2025 at 14:00, 6 hours ago

Boron One Holdings Inc. Signs Letter of Intent
Published on 05/05/2025 at 14:00, 6 hours ago

Newsmax Hits 20 Million Followers on Social Media
Published on 05/05/2025 at 13:30, 6 hours 30 minutes ago

EV Nickel Reports CarLang A PEA: Robust Economics for Large Scale Nickel Project

View all ACCESSWIRE

EQS Group

Published on 05/05/2025 at 19:05, 54 minutes ago

namR: Homologation du protocole de conciliation pour la cession d’actifs auprès d’Addactis
Published on 05/05/2025 at 19:00, 1 hour ago

PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 28 AVRIL 2025 au 02 MAI 2025
Published on 05/05/2025 at 18:30, 1 hour 29 minutes ago

Avolta Expands at JFK Terminal 5 with New Dining, Retail, and Video Gaming Experiences
Published on 05/05/2025 at 18:00, 2 hours ago

E-PANGO: Composition du capital au 30 avril 2025
Published on 05/05/2025 at 17:55, 2 hours 5 minutes ago

AFYREN and Südzucker celebrate 5 years of strategic bioeconomy partnership

Les Echos

Published on 05/05/2025 at 19:00, 1 hour ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 05/05/2025 at 19:00, 1 hour ago

ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES AVRIL 2025
Published on 05/05/2025 at 19:00, 1 hour ago

ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 05/05/2025 at 19:00, 1 hour ago

ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES AVRIL 2025
Published on 05/05/2025 at 17:45, 2 hours 15 minutes ago

Fire safety: Chubb France deploys AMA's assisted reality for remote troubleshooting

View all LES ECHOS COMFI WIRE